Genscript Biotech (HKSE:01548) EV-to-EBIT : -3.85 (As of May. 28, 2024)

View and export this data going back to 2015. Start your Free Trial

What is Genscript Biotech EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Genscript Biotech's Enterprise Value is HK$9,747 Mil. Genscript Biotech's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-2,532 Mil. Therefore, Genscript Biotech's EV-to-EBIT for today is -3.85.

The historical rank and industry rank for Genscript Biotech's EV-to-EBIT or its related term are showing as below:

HKSE:01548' s EV-to-EBIT Range Over the Past 10 Years
Min: -36.74 Med: -7.25 Max: 198.61
Current: -3.85

During the past 10 years, the highest EV-to-EBIT of Genscript Biotech was 198.61. The lowest was -36.74. And the median was -7.25.

HKSE:01548's EV-to-EBIT is ranked worse than
100% of 425 companies
in the Biotechnology industry
Industry Median: 9.85 vs HKSE:01548: -3.85

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Genscript Biotech's Enterprise Value for the quarter that ended in Dec. 2023 was HK$35,416 Mil. Genscript Biotech's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-2,532 Mil. Genscript Biotech's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -7.15%.

Genscript Biotech EV-to-EBIT Historical Data

The historical data trend for Genscript Biotech's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genscript Biotech EV-to-EBIT Chart

Genscript Biotech Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

Get a 7-Day Free Trial

-34.07

-7.73

-16.24

-14.29

-14.02

Genscript Biotech Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EV-to-EBIT	Get a 7-Day Free Trial														-16.24	-	-14.29	-	-14.02

Competitive Comparison of Genscript Biotech's EV-to-EBIT

For the Biotechnology subindustry, Genscript Biotech's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genscript Biotech's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genscript Biotech's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Genscript Biotech's EV-to-EBIT falls into.

Genscript Biotech EV-to-EBIT Calculation

Genscript Biotech's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	9746.877	/	-2531.615
	=	-3.85

Genscript Biotech's current Enterprise Value is HK$9,747 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Genscript Biotech's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-2,532 Mil.

Genscript Biotech (HKSE:01548) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Genscript Biotech's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 )	=	EBIT	/	Enterprise Value (Q: Dec. 2023 )
	=	-2531.615	/	35416.3842
	=	-7.15 %

Genscript Biotech's Enterprise Value for the quarter that ended in Dec. 2023 was HK$35,416 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Genscript Biotech's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-2,532 Mil.

Genscript Biotech EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Genscript Biotech's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Genscript Biotech (HKSE:01548) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genscript Biotech Corp (HKSE:01548) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

GNNSF:USA G51:Germany

Address

No. 28, Yongxi Road, Jiangning Science Park, Jiangsu Province, Nanjing, CHN, 211100

Website

https://www.genscript.com

GenScript Biotech is a China-based provider of life science research services and products. Founded in 2002, it is best known for its gene synthesis capabilities, a widely used service by academics, biotech companies, and pharmaceutical companies around the world. Its business lines include life science research services and products, biologics development services under its ProBio brand, and industrial enzymes under its Bestzyme brand. Finally, it owns 57.1% of Nasdaq-listed Legend Biotech, whose key pipeline asset is a BCMA-targeting CAR-T treatment for multiple myeloma. We estimate that more than two thirds of GenScript's valuation is from its ownership stake in Legend.

Executives

Wang Luquan	2401 A concert party to an agreement to buy shares
Wang Ye	2101 Beneficial owner
Zhang Fangliang	2401 A concert party to an agreement to buy shares
Huang Lili	2202 Interest of your spouse
Hu Zhiyong	2201 Interest of corporation controlled by you
Jin Weihong	2201 Interest of corporation controlled by you
Genscript Corporation	2101 Beneficial owner
Hillhouse Fund V, L.p.	2201 Interest of corporation controlled by you
Hillhouse Investment Management V, Ltd.	2201 Interest of corporation controlled by you
Hillhouse Investment Management, Ltd.	2102 Investment manager
Gns Holdings Limited	2101 Beneficial owner
Hillhouse Capital Management V, Ltd.	2201 Interest of corporation controlled by you
Hillhouse Capital Management, Ltd.	2102 Investment manager

Genscript Biotech (HKSE:01548) Headlines

No Headlines